期刊文献+

反相高效液相色谱法测定4-羟基-3-甲氧基苯甲酸及间苯三酚对儿茶酚氧位甲基转移酶的抑制作用 被引量:1

Determination of 4-Hydroxy-3-Methoxy Benzoic Acid by RP-HPLC and Inhibitory Effect of Phloroglucinol on Catecholamine-O-Methyl Transferase
下载PDF
导出
摘要 目的建立反相高效液相色谱(RP-HPLC)法测定4-羟基-3-甲氧基苯甲酸含量和观察间苯三酚对儿茶酚氧位甲基转移酶(COMT)的抑制作用。方法利用COMT催化3,4-二羟基苯甲酸生成4-羟基-3-甲氧基苯甲酸的原理,通过提取小鼠肝脏匀浆中的COMT 20μL,在反应体系中分别加入1×10-3mol·L-1邻苯二酚及5×10-3,1×10-3,2×10-4mol·L-1间苯三酚各10μL,利用RP-HPLC法测定产物生成量来分析间苯三酚对COMT的抑制作用。结果间苯三酚在5×10-3,1×10-3,2×10-4mol·L-13个浓度下对COMT活性均有抑制作用,抑制率分别为25.3%,17.6%,8.9%。结论间苯三酚对COMT活性具有抑制作用,但抑制作用弱于同浓度的邻苯二酚。 Objective To detect content of 4-hydroxy-3-methoxy benzoic acid by RP-HPLC and observe the inhibitory effect of phloroglucinol on catecholamine-O-methyl transferase( COMT). Methods This study used the principle of 3,4-dihydroxy benzoic acid transforming to 4-hydroxy-3-methoxy benzoic acid under COMT's catalytic action. COMT(20 μL) was extracted from mouse liver homogenate. In a reaction system,10 μL catecol(1 × 10^-3mol·L^-1 and 10 μL phloroglucinol(5 ×10^-3,1 ×10^-3and 2 × 10^-4mol·L^-1respectively) were added. Products were determined by RP-HPLC to analyze effects of 4-hydroxy-3-methoxy benzoic acid on COMT. Results Phloroglucinol had inhibitory effect on COMT activity at concentrations of 5× 10^-3mol·L^-11 × 10^-3mol·L^-1nd 2 × 10^-4mol · L-1,with the inhibition rate being 25. 3%,17. 6% and 8. 9%,respectively. Conclusion Phloroglucinol has an inhibitory effect on COMT activity,which is weaker than the effect of catechol of the same concentration.
出处 《医药导报》 CAS 北大核心 2014年第10期1303-1306,共4页 Herald of Medicine
关键词 间苯三酚 儿茶酚氧位甲基转移酶 色谱法 高效液相 反相 抑制作用 Phloroglucinol Catecholamine-O-methyl transferase HPLC Inhibitory effect
  • 相关文献

参考文献11

二级参考文献38

  • 1陈红兴,孙均,翟飞飞.间苯三酚注射液治疗胆绞痛的临床观察[J].中国血液流变学杂志,2008,18(4):537-538. 被引量:15
  • 2鲁宁,李立民.间苯三酚治疗原发性痛经的疗效观察[J].医学临床研究,2006,23(2):230-231. 被引量:13
  • 3全国妇女月经生理常数协作组.中国妇女月经生理常数的调查分析.中华妇产科杂志,1980,15:219-219.
  • 4Borthwick AD, Davies DE, Exall AM, et al. 2,5-Diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency [J]. J Med Ghem, 2006, 49(14):4159-4170.
  • 5Maxson WS, Rosenwaks Z. Textbook of gynecology [ M]. Philadelphia: W.B. Saunders, 2000. 513 -514.
  • 6Burnett MA, Antao V, Black A, et al. Prevalence of primary dysmenorrhea in Canada [ J ]. J Obstet Gynaecol Can, 2005, 27 (8) :765 -770.
  • 7Lee LK, Chen PC, Lee KK et al. Menstruation among adolescent girls in Malaysia: a cross-sectional school survey [ J]. Singapore Med J, 2006, 47(10) :869 -874.
  • 8Dogne JM, Hanson J, Supuran C, et al. Coxibs and cardiovascular side-effects : from light to shadow [ J ]. Curt Pharm Design, 2006, 12(8) :971 -975.
  • 9Yuan Y, Hunt RH. Assessment of the safety of selective cyclooxygenase-2 inhibitors : Where are we in 2003 [ J ] ? Inflammopharmacology, 2003, 11 (4) :337 -354.
  • 10Savage R. Cyclo-oxygenase-2 inhibitors: when should they be used in the elderly [J] ? Drug Aging, 2005, 22(3) :185 -200.

共引文献34

同被引文献17

引证文献1

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部